Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study Between the Roles of Intrauterine Misoprostol Versus the Sublingual Route for Prevention of Postpartum Blood Loss in Elective Cesarean Sections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 20-35 years.~2. BMI \< 30kg/m2.~3. Singleton pregnancy.~4. Full term pregnancies (recruiting from 37 weeks of gestation).~5. Elective cesarean section (previous one or two cesarean section).~Exclusion Criteria:~1. Active labour before 39 weeks.~2. Uterine over distension as due to multiple pregnancies or polyhydramnios.~3. Multipara \[parity ≥3\].~4. Pregnancy with obstetric haemorrhage such as placenta Previa, placental abruption or vasa Previa.~5. Moderate to severe anemia with HB \<9mg/dL.~6. Pregnancy with coagulopathy, thrombocytopenia or blood dyscrasias.~7. Women with uterine fibroids.~8. Medically complicated pregnancy (pregnancy induced hypertension, cardiovascular, DM, hepatic, or renal disorders).~9. Women with any contraindication for the use of misoprostol or oxytocin as a history of prostaglandin allergy and current medication which could cause severe drug interaction to prostaglandins such as topical dinoprostone, magnesium-containing antacids or quinapril.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- intrauterine misoprostol group (Group A) (Type: EXPERIMENTAL): 96 women receiving 400 mcg intrauterine misoprostol + IV oxytocin.
- sublingual misoprostol group (Group B) (Type: ACTIVE_COMPARATOR): : 96 women receiving 400 mcg sublingual misoprostol + IV oxytocin.

Based on this trial design, predict the completion outcome and termination type (if applicable).